ArticleRheumatology international2012
Elevated interleukin-18 and skewed Th1:Th2 immune response in lupus nephritis.
Article in Rheumatology international, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 23 citations in OpenAlex.
- Interleukin-18 in lupus nephritis: a meta-analysis of cytokine signaling dysregulation in immune-mediated nephropathy.Frontiers in immunology · 2025Pooled it
- Correlation between circulating interleukin-18 level and systemic lupus erythematosus: a meta-analysis.Scientific reports · 2021Pooled it
- IL-18 Promotes the Development of Lupus Nephritis by Activating the Wnt/β-Catenin Signaling Pathway in Renal Tubular Epithelial Cells.Inflammation · 2026Article
- Traditional Chinese medicine for lupus nephritis: modulation of autoimmune pathogenesis.Frontiers in pharmacology · 2025Review
- Lupus Nephritis from Pathogenesis to New Therapies: An Update.International journal of molecular sciences · 2024Review
- Article
- B Cell Subsets and Cellular Signatures and Disease Relapse in Lupus Nephritis.Frontiers in immunology · 2020Article
- Serum IL-18 as biomarker in predicting long-term renal outcome among pediatric-onset systemic lupus erythematosus patients.Medicine · 2016Article
- The Green Tea Polyphenol(-)-epigallocatechin-3-gallate and its beneficial roles in chronic kidney disease.Journal of translational internal medicine · 2016Review
- Serum Cytokines Th1, Th2, and Th17 Expression Profiling in Active Lupus Nephritis-IV: From a Southern Chinese Han Population.Mediators of inflammation · 2016Article
- An essential role of caspase 1 in the induction of murine lupus and its associated vascular damage.Arthritis & rheumatology (Hoboken, N.J.) · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is evidence that interleukin-18 plays a role in lupus nephritis (LN). Since interleukin -18 (IL-18) promotes polarization of the immune response toward Th1, we investigated level of IL-18 and assessed the phenotypic distribution of Th1 and Th2 type cells in LN. A predominance of Th1 type (IFN-γ+) cells and significant correlations with serum IL-18 was seen in the patients with LN compared to healthy controls. Although most patients were treated with high dosage of glucocorticoid and other immunosuppressive agents, higher level of IL-18 was found in both serum and glomeruli. However, there was no paralleled upregulation of its gene expression in peripheral blood mononuclear cells. Our findings indicate that the elevated IL-18 should be a symbol of disease activity and play a major role in the pathogenesis of LN by promoting cytokine imbalance towards Th1 type immune response. We conclude that patients with LN would benefit from it while the bioactivity of this cytokine was effectively counteracted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.